Table 1.
Clinical characteristics of patients by PD-L1 expression groups
| Negative group (TPS < 1%) |
Intermediate group (TPS 1%-49%) |
High group (TPS ≥ 50%) |
P value | |
|---|---|---|---|---|
| N = 248 | 124 (50%) | 93 (38%) | 31 (12%) | |
| Gender | ||||
| Male (n = 134) | 65 (52%) | 49 (53%) | 19 (61%) | 0.66 |
| Female (n = 117) | 59 (48%) | 44 (47%) | 12 (39%) | |
| Age (years) | ||||
| Median (range) | 58 (23 ~ 84) | 58 (27 ~ 80) | 60 (32 ~ 73) | 0.86 |
| TMB (Mut/Mb) | ||||
| Median (IQR) | 4.0 (2.01 ~ 5.36) | 3.4 (2.68 ~ 6.70) | 6.0 (4.02 ~ 14.41) | < 0.001* |
| TNB (Neo/Mb) | ||||
| Median (IQR) | 1.3 (0.67 ~ 2.68) | 1.3 (0.67 ~ 3.35) | 2.7 (1.34 ~ 4.02) | 0.09 |
| HLA LOH | ||||
| Negative | 98 (79%) | 77 (83%) | 21 (68%) | 0.16 |
| Positive | 26 (21%) | 16 (17%) | 10 (32%) |
*P values < 0.05 are indicated in bold and italics
TMB: tumor mutation burden (Mut/Mb mutations per megabase); TNB: tumor neoantigen burden (Neo/Mb neoantigens per megabase); HLA : human leukocyte antigen; LOH: loss of heterogeneity; IQR: interquartile range